In context
Selepressin was tested in the SEPSIS-ACT randomised trial in patients with septic shock. The study evaluated days alive without ventilator or vasopressor support. [1]
At a glance
- Type
- Investigational peptide
- Regulatory context
- Clinical research evidence, not confirmation of marketing authorisation.
- Evidence
- The trial evaluated a defined intensive-care population and did not establish an improvement in the primary outcome.
Clinical context
A receptor-specific physiological effect does not guarantee better patient outcomes. Trial results must be assessed using the prespecified outcome and the population actually studied. [1]
Safety and clinical context
Septic shock requires intensive-care treatment and monitoring. This is not an outpatient or self-treatment intervention.
Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.
Primary sources
Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.
- SEPSIS-ACT randomised clinical trial (2019) pubmed.ncbi.nlm.nih.gov